Company: NCEL
Filing Date: 2025-05-05
Form Type: 6-K
Source: 0001213900-25-039691
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-05-05
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of May 2025

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

Third Amendment to the Merger Agreement

On
May 5, 2025, NLS Pharmaceutics Ltd. (the “Company”) entered into a third amendment (the “Third Amendment”) to
the Agreement and Plan of Merger, dated November 4, 2024, and as previously amended on January 30, 2025 and on February 17, 2025 (the
“Merger Agreement”) among the Company, Kadimastem Ltd. (“Kadimastem”) and NLS Pharmaceutics (Israel) Ltd. (collectively,
the “Parties”).

Pursuant
to the Amendment, the Parties agreed to extend the Merger Agreement’s termination date from April 30, 2025 to June 30, 2025 in order
to complete the merger.

The
Parties remain focused on and fully committed to aligning their efforts to completing the merger as soon as possible and with the utmost
diligence. The Parties are actively working to fulfill all commitments related to the process and adhere to the requirements set forth
by all regulatory agents.

Safe Harbor Statement

This
Report of Foreign Private Issuer on Form 6-K contains expressed or implied forward-looking statements pursuant to U.S. Federal securities
laws. For example, the Company and Kadimastem are using forward-looking statements when they discuss the expected completion of the transaction.
These forward-looking statements and their implications are based on the current expectations of the management of the Company and Kadimastem
and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in
the